- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03478280
Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis
July 9, 2019 updated by: Anne Bregnhøj, Aarhus University Hospital
A randomised, double-blind, placebo-controlled, trial to evaluate the efficacy of brodalumab monotherapy on vascular and systemic inflammation by 18F-FDG-PET/CT in subjects with moderate-to-severe plaque-type psoriasis who are candidates for systemic therapy
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anne Bregnhøj, MD, PhD
- Phone Number: +45 2183 5720
- Email: annebreg@rm.dk
Study Locations
-
-
-
Aarhus, Denmark, 8200
- Recruiting
- Aarhus University Hospital
-
Contact:
- Anne Bregnhøj, PhD
- Email: annebreg@rm.dk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent obtained from the subject prior to performing any protocol-related procedures.
- Age 40 and above.
- Diagnosis of chronic plaque psoriasis confirmed by a dermatologist
- PASI ≥ 10
Exclusion Criteria:
- Non-Danish speaking
- Known or suspected allergy or reaction to any component of the IMP formulation.
- History of inflammatory bowel disease, arthritis (not including psoriatic arthritis), systemic lupus erythematosus, and active inflammatory skin diseases.
- A history of malignancies within the past five years (excluding localized non-melanoma skin cancer).
- Topical corticosteroid treatment (class III or stronger) and/or ultraviolet type B phototherapy within 2 weeks prior to randomization
- Treatment with psoralen plus ultraviolet type A photochemotherapy, methotrexate, cyclosporine, acitretin, or fumaric acid esters within 4 weeks prior to randomization.
- Treatment with adalimumab, etanercept, infliximab, cosentyx, or ixekizumab within 12 weeks, ustekinumab within 24 weeks, or other immunosuppressive or anti-inflammatory agents within 5 half-lives of the active substance prior to the FDG-PET/CT, respectively.
- Scheduled surgery during the trial period (expect minor minimally invasive procedures).
- Systemic infection or fever within 7 days prior to FDG-PET/CT.
- Severe obesity (> 150 kg due to a PET/CT scanner limitation).
- Presence of uncontrolled diabetes mellitus (HbA1c > 75 mmol/mol and/or blood sugar > 11.1 mmol/l and/or clinical judgment).
- History of coagulation defects (clinical judgment).
- Active or latent tuberculosis requiring treatment.
- Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb) or hepatitis C virus antibody (anti-HCV) serology at screening. Subjects with positive HBsAb may be randomised provided they are hepatitis B vaccinated and have negative HBsAg and HBcAb.
- History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral medications as determined by medical history and/or subject's verbal report.
- No history of varicella zoster infection and negative varicella antibody test (until varicella vaccination is completed).
- History of chronic alcohol or drug abuse within 12 months prior to screening, or any condition associated with poor compliance as judged by the investigator.
- History of intravenous drug use.
- History of attempted suicide or is at significant risk of suicide.
- Major surgery within the past 3 months.
- Pregnancy or lactation (Women of childbearing potential must use a highly effective* form of birth control (confirmed by the investigator) throughout the trial and until 12 weeks after discontinuation of treatment with brodalumab.
- Claustrophobia.
- Reduced renal function (serum creatinine > 200 μmol/L or cr-EDTA clearance < 30 ml/min)
Any disorder, including but not limited to, cardiovascular, lung, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, immunological, psychiatric, or major physical impairment that is not stable, in the opinion of the investigator, and could:
- Affect the safety of the subject throughout the trial.
- Influence the findings of the trial or their interpretations.
Impede the subject's ability to complete the entire duration of trial.
- A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year) such as bilateral tubal occlusion, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), sexual abstinence (when this is in line with the preferred and usual life style of the subject), vasectomised partner (given that the subject is monogamous). The subjects must have used the contraceptive method continuously for at least 1 month prior to the pregnancy test. A female is defined as not being of child bearing potential if she is postmenopausal (at least 12 months with no menses without an alternative medical cause prior to screening), or surgically sterile (hysterectomy, bilateral salpingectomy or bilateral oophorectomy).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Brodalumab
Subjects will receive 210 mg of Kyntheum administered by subcutaneous injection at Weeks 0, 1 and 2 followed by 210 mg every other week (EOW) thereafter.
|
Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
Other Names:
|
Placebo Comparator: Placebo
Subjects will receive placebo doses administered by subcutaneous injection at Weeks 0, 1 and 2 followed by placebo EOW thereafter.
|
Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The aortic wall inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo.
Time Frame: 16 weeks
|
The average of maximum TBR values (MeanTBRmax) of the entire aorta at baseline and at week 16
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The splenic inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo.
Time Frame: 16 weeks
|
The spleen-to-liver ratio (SLR) based on splenic and liver mean standardised uptake values (SUVmean)
|
16 weeks
|
The aortic wall subsegment inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo.
Time Frame: 16 weeks
|
The average of maximum TBR values (MeanTBRmax) of the ascending, aortic arch, descending, suprarenal, and infrarenal aorta at baseline and at week 16
|
16 weeks
|
The skin inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo.
Time Frame: 16 weeks
|
Severity of psoriasis measured by PASI score at baseline and at week 16
|
16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 15, 2018
Primary Completion (Anticipated)
March 15, 2020
Study Completion (Anticipated)
March 15, 2020
Study Registration Dates
First Submitted
March 13, 2018
First Submitted That Met QC Criteria
March 20, 2018
First Posted (Actual)
March 27, 2018
Study Record Updates
Last Update Posted (Actual)
July 10, 2019
Last Update Submitted That Met QC Criteria
July 9, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PsoPET2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Brodalumab
-
AmgenWithdrawnAxial SpondyloarthritisUnited States, Canada
-
Bausch Health Americas, Inc.TerminatedPsoriasisUnited States, Germany, Poland, Switzerland, France, Canada
-
Bausch Health Americas, Inc.CompletedPsoriatic ArthritisUnited States, France, Hungary, Mexico, Poland, Germany, Canada, Greece, Russian Federation, Latvia
-
Kyowa Kirin Co., Ltd.CompletedPsoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic ErythrodermaJapan
-
MedDerm AssociatesTerminated
-
Bausch Health Americas, Inc.TerminatedPsoriatic ArthritisUnited States, Italy, Spain, Hungary, Belgium, Mexico, Poland, Switzerland, United Kingdom, Russian Federation, Canada, Greece, France, Bulgaria, Slovakia, Estonia, Czech Republic
-
Bausch Health Americas, Inc.TerminatedModerate to Severe Plaque PsoriasisUnited States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
-
Bausch Health Americas, Inc.TerminatedPlaque PsoriasisUnited States, Belgium, Italy, Hungary, Poland, Australia, France, Greece, Russian Federation, Latvia, Canada
-
Rockefeller UniversityValeant PharmaceuticalsCompletedHidradenitis SuppurativaUnited States
-
Kyowa Kirin Co., Ltd.Completed